KOSDAQBiotech & Pharma424870

ImmuneOncia Therapeutics

₩2,320▼ 1.69%2026-11-18 close
Market Cap
₩212.1B
Turnover
₩300M
Volume
120K
Shares out.
91.4M
PER
—
PBR
—
EPS
-₩342
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Clinical data builds as losses persist

ImmuneOncia Therapeutics booked KRW 111 million in 2025 revenue against a KRW 28 billion operating loss, and with losses in five straight quarters, clinical readouts and funding are the next checkpoints.

  1. 1

    The 2025 operating loss widened to KRW 28 billion from KRW 12.6 billion in 2024, while revenue fell 83.0% to KRW 111 million.

  2. 2

    The third-quarter 2026 operating loss of KRW 9.13 billion was wider than the second quarter's KRW 4.27 billion but narrower than KRW 10.6 billion in the third quarter of 2025.

  3. 3

    IMC-002 reported a 25% objective response rate in a Phase 1b triple-negative breast cancer study, and MFDS approved a pancreatic cancer cohort on August 4, 2026.

  4. 4

    IMC-001 holds orphan drug designation in Korea and targets a 2029 marketing application, but a June 2026 press report put pre-commercialization costs at KRW 125.9 billion against KRW 18.5 billion of targeted licensing income.

  5. 5

    A KRW 81.8 billion rights issue was completed in May 2026, and the Korea Exchange decision on designating the company for unfaithful disclosure is due November 20, 2026.

02

Business structure

ImmuneOncia Therapeutics is a biotech developing immuno-oncology candidates, listed on KOSDAQ in May 2025. Its largest shareholder is Yuhan, with a stake reported at 65.92% as of February 2026. The core pipeline consists of IMC-001 (danburstotug), a PD-L1 antibody, and IMC-002, a CD47 antibody.

IMC-001 targets NK/T-cell lymphoma as its first indication and received orphan drug designation in Korea in January 2026, while a Phase 2 study in tumor mutational burden-high solid tumors is ongoing. In Phase 2 monotherapy, an objective response rate of 79% and a complete response rate of 63% were reported.

IMC-002 is designed to recognize glycosylation differences between cancer and normal cells and binds selectively to cancer cells. After liver, triple-negative breast and biliary tract cancers, a pancreatic cancer cohort was added in August 2026, combined with lenvatinib.

On manufacturing, the company signed an IMC-001 production agreement with CDMO Lonza, securing an integrated DS and DP network. Revenue was KRW 111 million in 2025, so the pipeline is a more practical unit of analysis than revenue segments.

The company runs a two-track strategy of domestic direct commercialization and overseas licensing. Both PD-L1 and CD47 are targets pursued by many global drugmakers, so differentiation rests on blood toxicity management and expansion into solid tumor indications.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩0-₩10.6B—
2025Q4₩0-₩9.6B—
2026Q1₩0-₩5.8B—
2026Q2₩0-₩4.3B—
2026Q3₩0-₩9.1B—
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2024₩700M-₩12.6B-₩5.7B−1924.8%−29.3%34.9%
2025₩100M-₩28B-₩27.4B−25182.0%−96.3%16.6%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-16

04

Earnings analysis

Revenue fell 83.0% to KRW 111 million in 2025 from KRW 6.5 million... more precisely, from KRW 655 million in 2024. Over the same period, the operating loss widened from KRW 12.6 billion to KRW 28 billion, and the operating margin moved from -1,924.8% to -25,182.0%.

The key feature of 2025 is that the operating loss grew while revenue shrank sharply. Net loss attributable to controlling shareholders rose from KRW 5.69 billion to KRW 27.4 billion, and net loss including non-controlling interests was reported at the same amounts.

In 2025 the operating loss and the controlling-shareholder net loss were nearly equal, so non-operating items had little effect on the bottom line. Both 2024 and 2025 were loss years, making two consecutive years of losses.

The debt-to-equity ratio fell to 16.6% at end-2025 from 34.9% in 2024, with total equity of KRW 28.4 billion and total liabilities of KRW 4.73 billion. Operating cash flow worsened from negative KRW 14.7 billion in 2024 to negative KRW 22.8 billion in 2025.

Quarterly operating losses moved from KRW 10.6 billion in the third quarter of 2025 to KRW 9.57 billion, KRW 5.75 billion and KRW 4.27 billion through the second quarter of 2026, before widening to KRW 9.13 billion in the third quarter.

Controlling-shareholder net losses followed the same pattern, falling to KRW 3.9 billion in the second quarter of 2026 and rising to KRW 8.1 billion in the third quarter. Net losses attributable to controlling shareholders over the last four quarters totaled KRW 27 billion.

The reason for the renewed third-quarter widening should be checked against the expense items in the quarterly report, particularly the timing of spending on clinical expansion.

05

Industry analysis

In immuno-oncology, PD-1 and PD-L1 agents remain the core of treatment standards, while CD47 is viewed as a next-generation checkpoint target that lets cancer cells evade macrophage phagocytosis. The largest hurdle for the CD47 class has been blood toxicity, so safety data has been treated as decisive for development.

At ASCO 2026, the IMC-002 Phase 1b study reported no thrombocytopenia or leukopenia, with grade 3 anemia in 6 patients and hemolytic anemia in 5 patients described as manageable.

In the same study's 12 triple-negative breast cancer patients, the objective response rate was 25% and disease control rate 75%, but the small sample limits interpretation. At AACR in April 2026, Cryo-EM analysis showed the mechanism by which IMC-002 minimizes binding to normal red blood cells.

A June 2026 press report estimated the initial domestic market for IMC-001 in NK/T-cell lymphoma at KRW 6 billion to KRW 15 billion a year. Even an optimistic scenario applying a 50% share to 500 new patients implies KRW 25 billion to KRW 30 billion a year.

That scale is small for a large commercial product, so combination indications and licensing are the key variables for the revenue model. Unlike listed biotechs that already generate revenue, ImmuneOncia remains at an early development stage, so clinical data and licensing track record are the relevant benchmarks.

06

Outlook

The company's commercialization schedule targets a 2029 marketing application for IMC-001 and a 2030 domestic launch.

CEO Kim Heung-tae said that because antibody drugs need at least three years of CMC process certification, work would have to start in April 2026 to hit a 2030 launch, according to a March 2026 shareholder briefing.

The company has set a target of 50% share within three years of launch, relying on Yuhan's sales infrastructure. The IMC-001 Phase 2 study is expanding into TMB-high solid tumors, with enrollment reported to finish within 2026. TMB-H data were expected between 2027 and 2028, according to a April 2026 report.

IMC-002 plans to secure follow-up clinical data after the pancreatic cohort and pursue global licensing, per a November 1, 2026 report.

A June 2026 press report put IMC-001 licensing targets at KRW 18.5 billion in total for 2027 and 2028, against KRW 125.9 billion in pre-commercialization costs, which makes partnering results the central variable.

The February 2026 rights issue was set at KRW 120 billion, and KRW 81.8 billion was reported as completed in May 2026. Yuhan has a lock-up through 2028 and says it has no plan to sell. The final decision on the unfaithful disclosure designation is due November 20, 2026.

07

Valuation

PER
—
PBR
—
ROE
-41.6%
EPS
-₩342
BPS
—
Dividend per share
₩0

Earnings-based valuation is hard to interpret for this company. Because net losses over the last four quarters leave the P/E ratio uncalculated, and dividend income is not a current feature, income-based comparisons have limited use.

On an asset basis, total equity was KRW 28.4 billion at end-2025, and the May 2026 rights issue increased equity afterward, so a book-value comparison is more accurate using financial statements from the 2026 annual report onward.

Even so, market capitalization sits well above year-end 2025 equity, so the share price leans more on licensing and approval prospects of the pipeline than on current revenue.

The stock has shown large one-day moves on clinical expansion and disclosure news, rising 17% on the day of the September 28, 2026 pancreatic cancer cohort news. This news sensitivity is a factor to consider when reading multiples for a loss-making company.

Industry-average multiple comparisons have limited applicability when earnings are negative, so asset-based indicators and event-driven variables carry more weight.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-16

08

Bull factors

Accumulating clinical response and safety data

IMC-002 showed a 25% objective response rate, 75% disease control and 42% clinical benefit rate in a Phase 1b triple-negative breast cancer cohort presented at ASCO 2026 on May 31, 2026. According to the company, thrombocytopenia and leukopenia, the main CD47-class side effects, were not observed.

IMC-001 recorded a 79% objective response rate and 63% complete response rate in Phase 2 monotherapy, reported in April 2026. Both candidates are now extending data into additional solid tumor indications.

Regulatory designations and approval path

IMC-001 received orphan drug designation in Korea in January 2026, and the company also obtained innovative drug fast-track review (GIFT) designation from MFDS. The first indication is relapsed or refractory NK/T-cell lymphoma, with broader use planned through combination therapy after domestic approval.

The company targets a 2029 marketing application and a 2030 domestic launch. Orphan designation is a support system for diseases with limited treatment options, which gives the program a defined regulatory route.

Funding and production base in place

A KRW 81.8 billion rights issue was completed in May 2026, providing funds for IMC-001 commercialization preparation and R&D.

The company signed a production agreement with CDMO Lonza, securing an integrated DS and DP manufacturing network that is read as preparing for licensing-grade quality data and commercial production.

The amount raised differs from the originally planned KRW 120 billion, but the funding base and production setup are both in place.

09

Bear factors

Persistent losses and a thin revenue base

Revenue fell 83.0% to KRW 111 million in 2025 while the operating loss widened to KRW 28 billion. The operating margin stood at -25,182.0%, showing the loss burden relative to the revenue base. Losses have continued for five straight quarters from the third quarter of 2025 through the third quarter of 2026.

The third-quarter 2026 operating loss of KRW 9.13 billion was wider than the prior quarter, reversing the earlier narrowing trend.

Gap between commercialization cost and targeted income

A June 2026 press report put IMC-001 licensing targets at KRW 3.5 billion in 2027 and KRW 15 billion in 2028, KRW 18.5 billion in total, against pre-commercialization costs of KRW 125.9 billion.

The same report estimated the initial domestic market at KRW 6 billion to KRW 15 billion a year, and an optimistic scenario at KRW 25 billion to KRW 30 billion a year. These figures show that the gap between cost and expected income must be closed through partnering.

Disclosure delays and unfaithful disclosure process

The company disclosed the application for a change to its IMC-002 clinical trial plan (filed July 1, 2026) and its approval (granted August 4, 2026) more than two months and over one month late.

The Korea Exchange issued a notice of intent to designate it as an unfaithful disclosure company on October 28, 2026, with a final decision due November 20, 2026. Its recent one-year penalty points stood at 0.0, but a designation with 8 points or more could lead to a one-day trading suspension. The company says the delay was a disclosure matter, not a new clinical setback.

10

Risk factors

Clinical data sample size and stage

The IMC-002 triple-negative breast cancer result rests on 12 patients, which limits interpretation. TMB-H solid tumor data for IMC-001 are expected between 2027 and 2028, and the pancreatic combination study is at an early enrollment stage. Whether clinical results translate into approval and sales remains uncertain. If follow-up data disappoint, licensing terms could also change.

Funding needs and dilution

Operating cash flow worsened to negative KRW 22.8 billion in 2025. The 2026 rights issue was planned at KRW 120 billion, but completed proceeds were reported at KRW 81.8 billion, raising the possibility of adjusting the funding plan.

A June 2026 press report noted that commercialization costs far exceed licensing targets, making overseas partnering the key to completion. Additional share issuance could lead to dilution risk.

Regulatory timeline and disclosure credibility

The final decision on the unfaithful disclosure designation is due November 20, 2026, and market confidence in disclosure practice is a near-term risk. Because the company says antibody drug process certification takes at least three years, any CMC delay could push back the 2030 launch target. The timing of the 2029 approval filing may also shift depending on MFDS review.

11

What to watch next

  1. November 20, 2026

    Korea Exchange final decision on unfaithful disclosure designation. Whether trading is suspended depends on the penalty points assigned, making this the first test of the company's disclosure process.

  2. By year-end 2026

    Completion of patient enrollment in the IMC-001 Phase 2 study in TMB-high solid tumors and related disclosure. Enrollment completion is the precondition for the 2027–2028 data timeline.

  3. End of March 2027

    Deadline for the 2026 annual report. It will confirm full-year 2026 revenue, operating loss and equity after the rights issue as regulatory filings.

  4. 2027–2028

    Timing of TMB-H data for IMC-001 and whether follow-up IMC-002 data are disclosed. These results will be the core basis for overseas licensing talks and the IMC-001 commercialization path.

12

Overall view

ImmuneOncia Therapeutics is a development-stage immuno-oncology company with KRW 111 million in 2025 revenue, an operating loss widened to KRW 28 billion, and losses in five consecutive quarters through the third quarter of 2026.

Positive factors include the IMC-002 Phase 1b safety data, IMC-001 orphan designation and Phase 2 response rates, the Lonza production agreement, and the completed KRW 81.8 billion rights issue.

Negative factors include a funding structure where commercialization costs far exceed targeted licensing income, small-sample clinical data, and the unfaithful disclosure process tied to delayed disclosure of clinical expansion.

The debt-to-equity ratio fell to 16.6%, but operating cash outflow widened to negative KRW 22.8 billion, making fundraising capacity the central variable.

Quarterly operating losses narrowed to KRW 4.27 billion in the second quarter of 2026 before widening to KRW 9.13 billion in the third quarter, so no single trend is yet visible.

The next checkpoints are the November 20, 2026 designation decision, enrollment completion in the IMC-001 Phase 2 study within 2026, and the 2026 annual report due by end-March 2027. This report contains no buy or sell opinion and no target price, and figures are based on DART regular report values and press reports.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. mt.co.kr
  2. thebionews.net
  3. hitnews.co.kr
  4. newsway.co.kr
  5. thebionews.net
  6. widedaily.com
  7. pinpointnews.co.kr
  8. job-post.co.kr
  9. image-ppubs.uspto.gov
  10. immuneoncia.com
  11. vegannews.co.kr
  12. dealsite.co.kr
  13. m.news.nate.com
  14. biotimes.co.kr
  15. press9.kr
  16. news.nate.com
  17. news.nate.com
  18. news.nate.com

Report written 2026-11-17 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis